Research ExplorerPublicationsConcordance of clinical and molecular breast cancer subtypin...

Concordance of clinical and molecular breast cancer subtyping in the context of preoperative chemotherapy response.

Standard

Concordance of clinical and molecular breast cancer subtyping in the context of preoperative chemotherapy response. / de Ronde Jorma, J; Hannemann, Juliane; Halfwerk, Hans; Mulder, Lennart; Straver, Marieke E; Peeters, Vrancken; Marie-Jeanne, T F D; Wesseling, Jelle; van de Vijver, Marc; Wessels, Lodewyk F A; Rodenhuis, Sjoerd.

In: BREAST CANCER RES TR, Vol. 119, No. 1, 1, 2010, p. 119-126.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

de Ronde Jorma, J, Hannemann, J, Halfwerk, H, Mulder, L, Straver, ME, Peeters, V, Marie-Jeanne, TFD, Wesseling, J, van de Vijver, M, Wessels, LFA & Rodenhuis, S 2010, 'Concordance of clinical and molecular breast cancer subtyping in the context of preoperative chemotherapy response.', BREAST CANCER RES TR, vol. 119, no. 1, 1, pp. 119-126. <http://www.ncbi.nlm.nih.gov/pubmed/19669409?dopt=Citation>

APA

de Ronde Jorma, J., Hannemann, J., Halfwerk, H., Mulder, L., Straver, M. E., Peeters, V., Marie-Jeanne, T. F. D., Wesseling, J., van de Vijver, M., Wessels, L. F. A., & Rodenhuis, S. (2010). Concordance of clinical and molecular breast cancer subtyping in the context of preoperative chemotherapy response. BREAST CANCER RES TR, 119(1), 119-126. [1]. http://www.ncbi.nlm.nih.gov/pubmed/19669409?dopt=Citation

Vancouver

de Ronde Jorma J, Hannemann J, Halfwerk H, Mulder L, Straver ME, Peeters V et al. Concordance of clinical and molecular breast cancer subtyping in the context of preoperative chemotherapy response. BREAST CANCER RES TR. 2010;119(1):119-126. 1.

Bibtex

@article{79067b0a7bd442ca972bf66af80ba1ad,
title = "Concordance of clinical and molecular breast cancer subtyping in the context of preoperative chemotherapy response.",
abstract = "ER, PR and HER2 status in breast cancer are important markers for the selection of drug therapy. By immunohistochemistry (IHC), three major breast cancer subtypes can be distinguished: Triple negative (TN(IHC)), HER2+(IHC) and Luminal(IHC) (ER+(IHC)/HER2-(IHC)). By using the intrinsic gene set defined by Hu et al. five molecular subtypes (Basal(mRNA), HER2+(mRNA), Luminal A(mRNA), Luminal B(mRNA) and Normal-like(mRNA)) can be defined. We studied the concordance between analogous subtypes and their prediction of response to neoadjuvant chemotherapy. We classified 195 breast tumors by both IHC and mRNA expression analysis of patients who received neoadjuvant treatment at the Netherlands Cancer institute for Stage II-III breast cancer between 2000 and 2007. The pathological complete remission (pCR) rate was used to assess chemotherapy response. The IHC and molecular subtypes showed high concordance with the exception of the HER2+(IHC) group. 60% of the HER2+(IHC) tumors were not classified as HER2+(mRNA). The HER2+(IHC)/Luminal A or B(mRNA) group had a low response rate to a trastuzumab-chemotherapy combination with a pCR rate of 8%, while the HER2+(mRNA) group had a pCR rate of 54%. The Luminal A(mRNA) and Luminal B(mRNA) groups showed similar degrees of response to chemotherapy. Neither the PR status nor the endocrine responsiveness index subdivided the ER+(IHC) tumors accurately into Luminal A(mRNA) and Luminal B(mRNA) groups. Molecular subtyping suggests the existence of a HER2+(IHC)/Luminal(mRNA) group that responds poorly to trastuzumab-based chemotherapy. For Luminal(IHC) and triple negative(IHC) tumors, further subdivision into molecular subgroups does not offer a clear advantage in treatment selection.",
author = "{de Ronde Jorma}, J and Juliane Hannemann and Hans Halfwerk and Lennart Mulder and Straver, {Marieke E} and Vrancken Peeters and Marie-Jeanne, {T F D} and Jelle Wesseling and {van de Vijver}, Marc and Wessels, {Lodewyk F A} and Sjoerd Rodenhuis",
year = "2010",
language = "Deutsch",
volume = "119",
pages = "119--126",
journal = "BREAST CANCER RES TR",
issn = "0167-6806",
publisher = "Springer New York",
number = "1",

}

RIS

TY - JOUR

T1 - Concordance of clinical and molecular breast cancer subtyping in the context of preoperative chemotherapy response.

AU - de Ronde Jorma, J

AU - Hannemann, Juliane

AU - Halfwerk, Hans

AU - Mulder, Lennart

AU - Straver, Marieke E

AU - Peeters, Vrancken

AU - Marie-Jeanne, T F D

AU - Wesseling, Jelle

AU - van de Vijver, Marc

AU - Wessels, Lodewyk F A

AU - Rodenhuis, Sjoerd

PY - 2010

Y1 - 2010

N2 - ER, PR and HER2 status in breast cancer are important markers for the selection of drug therapy. By immunohistochemistry (IHC), three major breast cancer subtypes can be distinguished: Triple negative (TN(IHC)), HER2+(IHC) and Luminal(IHC) (ER+(IHC)/HER2-(IHC)). By using the intrinsic gene set defined by Hu et al. five molecular subtypes (Basal(mRNA), HER2+(mRNA), Luminal A(mRNA), Luminal B(mRNA) and Normal-like(mRNA)) can be defined. We studied the concordance between analogous subtypes and their prediction of response to neoadjuvant chemotherapy. We classified 195 breast tumors by both IHC and mRNA expression analysis of patients who received neoadjuvant treatment at the Netherlands Cancer institute for Stage II-III breast cancer between 2000 and 2007. The pathological complete remission (pCR) rate was used to assess chemotherapy response. The IHC and molecular subtypes showed high concordance with the exception of the HER2+(IHC) group. 60% of the HER2+(IHC) tumors were not classified as HER2+(mRNA). The HER2+(IHC)/Luminal A or B(mRNA) group had a low response rate to a trastuzumab-chemotherapy combination with a pCR rate of 8%, while the HER2+(mRNA) group had a pCR rate of 54%. The Luminal A(mRNA) and Luminal B(mRNA) groups showed similar degrees of response to chemotherapy. Neither the PR status nor the endocrine responsiveness index subdivided the ER+(IHC) tumors accurately into Luminal A(mRNA) and Luminal B(mRNA) groups. Molecular subtyping suggests the existence of a HER2+(IHC)/Luminal(mRNA) group that responds poorly to trastuzumab-based chemotherapy. For Luminal(IHC) and triple negative(IHC) tumors, further subdivision into molecular subgroups does not offer a clear advantage in treatment selection.

AB - ER, PR and HER2 status in breast cancer are important markers for the selection of drug therapy. By immunohistochemistry (IHC), three major breast cancer subtypes can be distinguished: Triple negative (TN(IHC)), HER2+(IHC) and Luminal(IHC) (ER+(IHC)/HER2-(IHC)). By using the intrinsic gene set defined by Hu et al. five molecular subtypes (Basal(mRNA), HER2+(mRNA), Luminal A(mRNA), Luminal B(mRNA) and Normal-like(mRNA)) can be defined. We studied the concordance between analogous subtypes and their prediction of response to neoadjuvant chemotherapy. We classified 195 breast tumors by both IHC and mRNA expression analysis of patients who received neoadjuvant treatment at the Netherlands Cancer institute for Stage II-III breast cancer between 2000 and 2007. The pathological complete remission (pCR) rate was used to assess chemotherapy response. The IHC and molecular subtypes showed high concordance with the exception of the HER2+(IHC) group. 60% of the HER2+(IHC) tumors were not classified as HER2+(mRNA). The HER2+(IHC)/Luminal A or B(mRNA) group had a low response rate to a trastuzumab-chemotherapy combination with a pCR rate of 8%, while the HER2+(mRNA) group had a pCR rate of 54%. The Luminal A(mRNA) and Luminal B(mRNA) groups showed similar degrees of response to chemotherapy. Neither the PR status nor the endocrine responsiveness index subdivided the ER+(IHC) tumors accurately into Luminal A(mRNA) and Luminal B(mRNA) groups. Molecular subtyping suggests the existence of a HER2+(IHC)/Luminal(mRNA) group that responds poorly to trastuzumab-based chemotherapy. For Luminal(IHC) and triple negative(IHC) tumors, further subdivision into molecular subgroups does not offer a clear advantage in treatment selection.

M3 - SCORING: Zeitschriftenaufsatz

VL - 119

SP - 119

EP - 126

JO - BREAST CANCER RES TR

JF - BREAST CANCER RES TR

SN - 0167-6806

IS - 1

M1 - 1

ER -